No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Here's Why PharmaBlock Sciences (Nanjing) (SZSE:300725) Has A Meaningful Debt Burden
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site
The Pharma Block Sciences Zhejiang Huishi production base has officially put into operation the 503 commercial GMP workshop.
Nanjing, February 18, 2025 /PR Newswire/ -- Nanjing Pharma Block Sciences Co., Ltd. (Company abbreviation: Pharma Block Sciences, Stock code: 300725) announced that its Zhejiang Hui Shi production base's 503 multi-functional commercial GMP workshop has officially begun operations. This workshop, with its scaled production capacity configuration, high-spec GMP production system, advanced automation, and low-carbon lean operation model, fully upgrades the development and production service capabilities from late-stage clinical trials to commercialization. 1. Focus on commercial production demand The 503 multi-functional commercial GMP workshop focuses on late-stage clinical and commercial production needs, with a total capacity reaching 1.
Guotou Securities: AI pharmaceuticals have entered a "qualitative change" stage, and commercialization applications are expected to be realized.
With the increase in the success rate of AI pharmaceutical research and development, AI drug manufacturing is expected to enter the stage of commercial realization. In terms of investment, it is recommended to focus on positive progress in areas such as technology platforms, collaborative projects, clinical milestones, and research and development pipelines.
